Table 2.
Antimicrobial tested | Enterococcus (n = 5) | Staphylococcus aureus (n = 51) | ||
---|---|---|---|---|
Mini API (n = 3) | Vitek (n = 2) | Mini API (n = 21) | Vitek (n = 30) | |
Amoxicillin | NP | NP | 100 | 100 |
Cefotaxime + clavulanate | NP | 50 | NP | 37 |
Ceftazidime + clavulanate | NP | 50 | NP | 37 |
Cefepime + tazobactam | NP | 50 | NP | 30 |
Tigecycline | NP | 0 | NP | NP |
Gentamycin | 33 | 50 | NP | NP |
Amikacin | 33 | 50 | NP | NP |
Ciproflox | 100 | 100 | 90 | 87 |
Levoflox | 100 | 100 | 75 | 80 |
Nalidixic acid | 100 | 100 | NP | NP |
Nitrofurantoin | 100 | 100 | 0 | 78 |
Tetracycline | 33 | 50 | 10 | 27 |
Doxycycline | 33 | 50 | 10 | 27 |
Minocycline | 33 | 50 | 10 | 27 |
Oxacillin | NP | NP | 73 | 67 |
Vancomycin** | 50 | 50 | 20 | 22 |
Teicoplanin | 33 | 50 | NP | 0 |
Daptomycin | NP | 0 | NP | 6 |
Linezolid | NP | 0 | NP | 3 |
NP: drug not in panel; **see Section 4.
Figures in the table are expressed in percentages.